Ibuprofen-Immobilized Thin Films: A Novel Approach to Improve the Clearance of Protein-Bound Uremic Toxins

• DOI: 10.1021/acsami.3c15291
• Publication Date: 2024-01-29T08:58:27Z
• Authors: Flávia S. C. Rodr...; Dialina Brilhante; Ana Macêdo; Rita F. Pires; Mónica Faria
• Keywords: Uremic Toxins; Ibuprofen; Human serum albumin

Chronic kidney disease (CKD), a pressing global health issue, affects millions and leads to end-stage renal (ESRD). Hemodialysis (HD) is crucial treatment for ESRD, yet its limited efficiency in removing protein-bound uremic toxins (PBUTs) results high morbidity mortality rates. A affinity of pharmaceutical drugs human serum albumin (HSA) can be leveraged compete effectively with PBUTs the same HSA binding sites, thereby enabling them capable displacing these toxins. One such drug ibuprofen (IBF), known very sharing site as indoxyl sulfate (IS). This study explores development IBF-immobilized cellulose acetate-based (CA-based) thin films. The films were created by reacting CA IBF-modified silica precursors at varying concentrations. presence IBF CA/TEOS/APTES-IBF-3 CA/TEOS-IBF-25 films, containing 3 25 wt % IBF, respectively, was confirmed through 1H NMR spectra. Competitive displacement assays indicated that while incorporation showed no significant enhancement IS displacement, film increased dialyzed 1.3 when normalized non-IBF Furthermore, there 1.2-fold decrease total percentage IS, free 3.0 times. Although direct systemic infusion HD patients achieves 2.4 times higher removal it impractical due risks poses ESRD patients. offer advantage localized binding, thus eliminating need exposure. innovative approach lays foundation developing more efficient membranes, aiming address challenging issue PBUT elimination potentially enhance quality life outcomes